Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment
By Dean Seal
Candel Therapeutics said regulators have granted orphan-drug designation to its CAN-3110 drug candidate as a treatment for recurrent high-grade glioma, an aggressive brain tumor.
The Needham, Mass., clinical-stage biopharmaceutical company said Thursday that the U.S. Food and Drug Administration's designation provides CAN-3110 with certain developmental financial incentives and, if approved, potentially up to seven years of marketing exclusivity in the U.S.
Orphan-drug designation is a special status given to drugs that show promise for potentially treating rare, or orphan, diseases that have fewer than 200,000 cases a year in the U.S.
CAN-3110 was previously granted the FDA's fast-track designation to expedite its development and review.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 30, 2024 08:45 ET (12:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
United States